$24.26
0.21% yesterday
NYSE, Jun 25, 10:13 pm CET
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Pfizer Stock price

$24.26
+0.94 4.03% 1M
-2.48 9.27% 6M
-2.27 8.56% YTD
-3.73 13.33% 1Y
-27.62 53.24% 3Y
-6.36 20.76% 5Y
-7.97 24.72% 10Y
-2.34 8.80% 20Y
NYSE, Closing price Wed, Jun 25 2025
-0.05 0.21%
ISIN
US7170811035
Symbol
PFE
Sector
Industry

Key metrics

Basic
Market capitalization
$137.9b
Enterprise Value
$182.7b
Net debt
$44.8b
Cash
$17.3b
Shares outstanding
5.7b
Valuation (TTM | estimate)
P/E
17.71 | 13.77
P/S
2.21 | 2.21
EV/Sales
2.93 | 2.93
EV/FCF
16.29
P/B
1.53
Dividends
DPS
$1.69
Yield 1Y | 5Y
6.97% | 4.17%
Growth 1Y | 5Y
2.42% | 4.09%
Payout 1Y | 3Y
119.86% | 68.28%
Increased
15 Years
Financials (TTM | estimate)
Revenue
$62.5b | $62.4b
EBITDA
$22.1b | $24.6b
EBIT
$16.9b
Net Income
$7.9b | $10.0b
Free Cash Flow
$11.2b
Growth (TTM | estimate)
Revenue
11.65% | -1.87%
EBITDA
40.29% | 11.80%
EBIT
56.33%
Net Income
2,651.13% | 24.73%
Free Cash Flow
119.74%
Margin (TTM | estimate)
Gross
74.57%
EBITDA
35.43% | 39.42%
EBIT
27.12%
Net
12.62% | 16.04%
Free Cash Flow
17.96%
Financial Health
Equity Ratio
41.33%
Return on Equity
9.11%
ROCE
9.87%
ROIC
11.23%
Debt/Equity
0.69
More
EPS
$1.37
FCF per Share
$1.97
Short interest
1.85%
Employees
81.00k
Rev per Employee
$790.00k
Show more

Is Pfizer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Pfizer Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Pfizer forecast:

9x Buy
36%
15x Hold
60%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Pfizer forecast:

Buy
36%
Hold
60%
Sell
4%

Financial data from Pfizer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
62,463 62,463
12% 12%
100%
- Direct Costs 15,887 15,887
1% 1%
25%
46,576 46,576
17% 17%
75%
- Selling and Administrative Expenses 14,169 14,169
3% 3%
23%
- Research and Development Expense 10,437 10,437
1% 1%
17%
22,131 22,131
40% 40%
35%
- Depreciation and Amortization 5,189 5,189
5% 5%
8%
EBIT (Operating Income) EBIT 16,942 16,942
56% 56%
27%
Net Profit 7,883 7,883
2,651% 2,651%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Pfizer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pfizer Stock News

Positive
Reuters
about one hour ago
Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies.
Neutral
Business Wire
about 2 hours ago
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving k...
Positive
Seeking Alpha
about 9 hours ago
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep discounts on P/E, EV/EBITDA, and P/B, with a strong 8.2% FCF yield and sector-leading 7% dividend. Risks include patent cliffs, U.S. drug price regulation, and R&D setbacks, but robust margins and ...
More Pfizer News

Company Profile

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Head office United States
CEO Albert Bourla
Employees 81,000
Founded 1849
Website www.pfizer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today